Pharmacovigilance
1. Signal summary (this week)
This briefing concerns patterns in third-party AI-generated answers only. It is not an adverse-event report and does not establish a confirmed safety signal.
For week ending 23 August 2026, monitoring identified 26 cross-response inconsistency flags, up from 24 last week (+2). The absolute count is therefore rising, although responses also increased from 120 to 140, so the flag rate was slightly lower.
The response-level category tally was: hedging/disclaimer 120; infection risk 87; IBD 40; overclaim language 33; contraindication 26; allergic reaction 23; dosing-specific 20; pregnancy/lactation 19; pediatric 17; biosimilar/generic 11; boxed warning 8; kidney 6; off-label 3. These are raw mentions across answers, not unique inconsistency flags.
2. Highest-priority inconsistencies
-
PI—pregnancy, breastfeeding, and infant live vaccines: Contraindication was mentioned in 2 variants and omitted in 5. The inconsistent classification could cause readers either to treat pregnancy as an absolute contraindication or to miss relevant label-based risk/benefit and infant-vaccination considerations.
-
PI—boxed warnings and infection risk: Contraindication was mentioned in 2 variants and omitted in 5; the answer set also inconsistently framed “boxed-warning-level” language. This could blur the distinction between a formal boxed warning, Warnings and Precautions, and situations in which treatment should be withheld.
-
PI—administration and injection instructions: Allergic reaction was mentioned in 5 variants and omitted in 2; infection risk was mentioned in 3 and omitted in 4. Omitting hypersensitivity and infection precautions from a practical administration answer could leave a patient without important “do not use/seek medical advice” safety information.
-
Brand—Cosentyx versus Humira for plaque psoriasis: Allergic reaction/hypersensitivity appeared in 1 variant and was omitted in 6. A comparative answer focused on effectiveness and common tolerability may therefore provide an incomplete safety picture.
-
Brand—Cosentyx versus Taltz counseling: IBD was mentioned in 1 variant and omitted in 6; infection risk was mentioned in 5 and omitted in 2; pregnancy/lactation was mentioned in 1 and omitted in 6. Relevant class and patient-selection considerations may be missed during treatment-choice counseling.
3. Recurring or worsening themes across weeks
Infection-risk mentions remain consistently high: 85, 37, 89, 78, 87 over the five weeks. IBD mentions are also recurrent (35, 23, 43, 32, 40) and increased 25% versus last week. Allergic-reaction mentions rose from 17 to 23, and pregnancy/lactation from 15 to 19. Contraindication mentions remain elevated overall (23, 9, 27, 27, 26), while boxed-warning mentions remain low but persistent (7, 3, 8, 7, 8). These trends indicate recurring answer instability rather than a newly emerging product safety finding.
4. Escalation recommendation
Flag to a human safety/medical reviewer this week. The repeated omission of contraindication-related content and inconsistent boxed-warning framing warrant documented review, particularly for PI questions. This remains an AI-content quality and safety communication concern—not a confirmed Cosentyx safety signal. Log other informational omissions and continue monitoring.
5. Recommended actions
- Perform a documented medical/regulatory review of the pregnancy/live-vaccine and boxed-warning question variants.
- Validate all answer variants against the current applicable Cosentyx prescribing information, including contraindications, hypersensitivity, infection, IBD, and vaccination language.
- Review the administration answers for device, refrigeration, infusion, and hypersensitivity instructions.
- Separately quality-check dosing outputs: variants conflict on four versus five loading doses and on maintenance timing.
- Add these question-topic pairs to next week’s trend review and regulatory-affairs sync.